Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 121.10

+0.4%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: T. Mann who wrote (258)	4/10/1997 1:36:00 PM
From: scaram(o)uche	of 961

T: Obligatory GILD-related comment......... thanks for raising the issue of "flares" after treatment with GS 840. I had forgotten about this. As I indicated, I'm developing a bit of enthusiasm toward GS 840....... not much, but GILD seems to be profiting from keeping it alive and from exposure to increasing numbers of patients, both in the HIV trials and in the HBV setting. I consider my investment in GILD to be relatively safe and wise without GS 840, so I'm a happy camper. Agouron overvalued? Patients are switching to Viracept. While you're wise to focus on coming competition, we've learned that side-effects will largely determine market share. Only one other PI is in advanced testing, and my own personal feel is that saq/nelf combinations will steal market share and make penetration a nightmare for those who follow. You didn't short it at 60? Great, glad to hear such. Cheers! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next